Health Care Costs

  • |

    We Fund the Science. They Set the $3.95 Million Price.

    ByPhil McCracken

    I followed the Kebilidi invoice and found NIH’s NCATS on the public-science side, PTC Therapeutics at the commercial finish line, and a stated price of $3.95 million waiting like it had its own congressional parking space. That does not mean public research invented every molecule or erased the company’s costs. It does mean taxpayers and patients deserve a seat at the pricing table when public support helped move a rare-disease therapy from scientific risk toward treatment.

    One-time gene therapies are complex and expensive; nobody is asking the lab to accept payment in inspirational refrigerator magnets. But complexity cannot be the magic word that makes public investment disappear from the conversation. The public helped build the runway, while private billing arrived dressed as the sole owner of aviation. Follow the invoice: government may not have created every part of Kebilidi, but families should not be treated like silent partners who receive only the receipt. Fair pricing and fair taxes are the minimum decent terms.

  • |

    Congress Finds the Express Lane

    ByMoses Pray

    Washington can become very prayerful about procedure when families need lower costs, clear answers, or a little public relief. Suddenly every hallway is a wilderness, every calendar is a mystery, and every promise must be studied by a committee that meets somewhere behind the boiler room. But when congressional comfort, party power, or protected money needs shelter, brothers and sisters, the Red Sea develops an express lane.

    That is the moral audit here: ordinary people get the church-basement folding chair and a casserole labeled “thoughts,” while the powerful get the padded front pew and an usher with a stopwatch. If mercy ever receives the same urgency as self-protection, Congress may accidentally discover governing. Peace be with them, and may someone hide the loopholes where they keep the hymnals.

  • |

    The Patent Labyrinth: Why Cheaper Meds Are Stuck in Traffic

    ByLee Keybum

    Big Pharma’s favorite maze game? Patents. They claim innovation, yet leave generic drugs entangled in legal red tape longer than a DMV line on a Monday morning. It’s the classic bait-and-switch: promise a cure, deliver a price tag thicker than a lawyer’s billable hour.

    While pharmaceutical giants wax poetic about breakthrough treatments, what they really offer is a roadmap to higher costs. Consider it a toll booth nightmare where your wallet holds its breath as if it’s being drafted by your gym contractor. With every delay, there’s another bureaucratic hurdle—and we’re all just paying the fare for the privilege.

End of content

End of content